Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Syndax Pharmaceuticals reported multiple Revuforj (revumenib) abstracts at EHA 2026. In ROAR (R/R NPM1m/KMT2Ar), interim ORR was 82% (9/11) with 64% (7/11) CR/CRh. In SNDX-5613-0708 (newly diagnosed NPM1m/KMT2Ar), CRc was 97% (34/35) and MRD negativity 86% (25/29). Post-HSCT AUGMENT-101 analysis showed 12-month OS 95%. In SAVE (R/R AML), ORR was 88% (37/42) and MRD negativity 68% (25/37).
How this was made
The 30-second read
Why it matters
The disclosed efficacy and MRD/OS datapoints across multiple AML genetic subtypes and treatment settings can shift investor expectations for revumenib’s pivotal frontline combination trials and competitive positioning in menin-inhibitor AML therapy.
Market read
Multiple high ORR/CR/MRD and favorable post-HSCT OS estimates at EHA can catalyze positive sentiment and re-rate probability-weighted outcomes for SNDX’s AML pipeline.
What to watch
Safety signals are described as consistent (no DS/QTc > Grade 3), but the article provides limited detail on longer-term tolerability, subgroup durability, and how these results compare to existing SOC benchmarks in the same settings.
Background
Syndax highlighted 12 revumenib abstracts at EHA 2026, spanning real-world ROAR interim results, phase 1 combination with intensive chemotherapy, post-HSCT outcomes (AUGMENT-101 post-hoc), and phase 1/2 SAVE combination data with venetoclax plus decitabine/cedazuridine.
Ticker impact
Syndax presented new EHA 2026 revumenib data, including ROAR real-world ORR 82% and SAVE combination ORR 88% in R/R AML subtypes.
Near-term sentiment likely positive for SNDX as investors price higher probability of successful pivotal frontline combination readouts; magnitude depends on prior expectations and any upcoming trial milestones.
The article discloses multiple new efficacy datapoints (ORR/CR/MRD/OS) across distinct cohorts, but it is still congress/early-stage and not a regulatory or definitive trial endpoint update.
Market effects
Positive read-through for menin-inhibitor/AML combination strategies (revumenib + venetoclax and HMA) and for investor appetite toward AML targeted therapies.
Primarily global biotech sentiment; Stockholm congress timing can drive same-week positioning in US-listed peers.
Reinforces competitive efficacy benchmarks in NPM1m/KMT2Ar/NUP98r AML, potentially affecting how the market values similar AML programs worldwide.
Counterpoint
High response rates may not translate into durable survival benefit yet; follow-up is still maturing in some cohorts, and post-HSCT resumption rates may confound durability.
Key entities
- companySyndax Pharmaceuticals
Commercial-stage biopharmaceutical company advancing revumenib (Revuforj) menin inhibitor.
- drugRevuforj (revumenib)
FDA-approved menin inhibitor evaluated across multiple AML subtypes and combinations.
- studyROAR
Multicenter real-world study providing interim ORR/CR/CRh and HSCT/resumption details.
- trialAUGMENT-101
Study providing post-HSCT post-hoc outcomes after patients resumed revumenib.
- trialSAVE
Phase 1/2 combination study of revumenib with venetoclax and decitabine/cedazuridine.
